Annotation Detail
Information
- Associated Genes
- CD274
- Associated Variants
-
CD274 EXPRESSION
CD274 EXPRESSION - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/743
- Gene URL
- https://civic.genome.wustl.edu/links/genes/11335
- Variant URL
- https://civic.genome.wustl.edu/links/variants/276
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Nivolumab,Pembrolizumab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26086854
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Nivolumab | Sensitivity | true |
| Pembrolizumab | Sensitivity | true |